Cost-Effectiveness of the Addition of Bevacizumab to First-Line Chemotherapy With Carboplatin and Paclitaxel in Patients With Non-Small Cell Lung Cancer.

MLA

Parody-Rúa, Elizabeth, and Cesar Augusto Guevara-Cuellar. “Cost-Effectiveness of the Addition of Bevacizumab to First-Line Chemotherapy With Carboplatin and Paclitaxel in Patients With Non-Small Cell Lung Cancer.” Value in Health Regional Issues, vol. 23, Dec. 2020, pp. 93–98. EBSCOhost, https://doi.org/10.1016/j.vhri.2020.04.005.

APA

Parody-Rúa, E., & Guevara-Cuellar, C. A. (2020). Cost-Effectiveness of the Addition of Bevacizumab to First-Line Chemotherapy With Carboplatin and Paclitaxel in Patients With Non-Small Cell Lung Cancer. Value in Health Regional Issues, 23, 93–98. https://doi.org/10.1016/j.vhri.2020.04.005

Chicago

Parody-Rúa, Elizabeth, and Cesar Augusto Guevara-Cuellar. 2020. “Cost-Effectiveness of the Addition of Bevacizumab to First-Line Chemotherapy With Carboplatin and Paclitaxel in Patients With Non-Small Cell Lung Cancer.” Value in Health Regional Issues 23 (December): 93–98. doi:10.1016/j.vhri.2020.04.005.